JO
TOVX icon

John Overdeck’s Theriva Biologics TOVX Stock Holding History

John Overdeck’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.87K Buy
15,456
+15
+0.1% +$4 ﹤0.01% 5017
2026
Q1 		$3.02K Sell
15,441
-26,896
-64% -$5.3K ﹤0.01% 4545
2025
Q4 		$8.91K Sell
42,337
-19,500
-32% -$5.77K ﹤0.01% 4030
2025
Q3 		$25.1K Buy
+61,837
New +$26.8K ﹤0.01% 3584
2024
Q4 		– Sell
-13,566
Closed -$18.7K – 3490
2024
Q3 		$18.7K Buy
+13,566
New +$66.2K ﹤0.01% 3023
2022
Q3 		– Sell
-645
Closed -$34K – 2829
2022
Q2 		$34K Sell
645
-8
-1% -$458 ﹤0.01% 2371
2022
Q1 		$47K Buy
653
+317
+94% +$21.6K ﹤0.01% 2495
2021
Q4 		$23K Sell
336
-516
-61% -$48.7K ﹤0.01% 4171
2021
Q3 		$98K Buy
852
+765
+879% +$95.2K ﹤0.01% 4086
2021
Q2 		$13K Buy
+87
New +$12.5K ﹤0.01% 3960
2019
Q1 		– Sell
-43
Closed -$6K – 3474
2018
Q4 		$6K Buy
+43
New +$10.2K ﹤0.01% 2901

Other funds holding TOVX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

John Overdeck's TOVX Position: Q2 2026 in Review

John Overdeck increased its Theriva Biologics (TOVX) stake by 0.1% in Q2 2026, buying an estimated $4 and bringing the position to 15,456 shares worth $3.87K. The position accounts for ﹤0.01% of the portfolio, ranked #5017.

John Overdeck first reported a position in TOVX in Q4 2018 and has held it in 11 quarters since. The position peaked at $98K in Q3 2021. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

  • John Overdeck held 15,456 shares of Theriva Biologics worth $3.87K as of Q2 2026.
  • John Overdeck bought 15 Theriva Biologics shares in Q2 2026, an estimated $4.
  • Theriva Biologics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #5017 holding.
  • John Overdeck first reported a position in Theriva Biologics in Q4 2018 and has held it in 11 quarters since.
  • John Overdeck's Theriva Biologics position peaked at $98K in Q3 2021.
  • 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.